$75K in expenses

The Foundation funds research activities to find a cure for Duchennes Muscular Dystrophy (DMD). Currently there are a number of clinical trials underway for drugs developed to treat various aspects of DMD. In September 2016, Sarepta Therapeutics, won FDA approval for the use of its drug Exondys 51 for the treatment of DMD patients that have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. In December 2019, Sarepta, won FDA approval for its new drug Vyondys 53 for the treatment of patients that have a confirmed mutation of the dystrophin gene connected to exon 53 skipping. Both treatments help approximately 21% of the patients afflicted with DMD.